|
SHPRH expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63180580159406E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.64479541098217E-12 |
| Normal-vs-Stage2 |
5.51780843238703E-13 |
| Normal-vs-Stage3 |
1.11022302462516E-15 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
6.378000E-01 |
| Stage1-vs-Stage3 |
1.148210E-01 |
| Stage1-vs-Stage4 |
2.977400E-03 |
| Stage2-vs-Stage3 |
1.198980E-01 |
| Stage2-vs-Stage4 |
1.413860E-02 |
| Stage3-vs-Stage4 |
1.998950E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63058455626697E-12 |
| Normal-vs-AfricanAmerican |
2.46279996396481E-10 |
| Normal-vs-Asian |
3.94129173741931E-14 |
| Caucasian-vs-AfricanAmerican |
2.480200E-01 |
| Caucasian-vs-Asian |
9.410000E-01 |
| AfricanAmerican-vs-Asian |
3.414000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62525548574877E-12 |
| Normal-vs-Female |
1.64013247427874E-12 |
| Male-vs-Female |
5.752200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.50990331349021E-14 |
| Normal-vs-Age(41-60Yrs) |
8.10462807976364E-15 |
| Normal-vs-Age(61-80Yrs) |
1.6269208202857E-12 |
| Normal-vs-Age(81-100Yrs) |
2.00969999974987E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.489400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.548000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.069200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.548800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.211800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.948600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.581100E-04 |
| Classical-VS-Follicular |
9.425200E-01 |
| Classical-VS-Other |
1.581400E-01 |
| Classical-VS-Normal |
1.70730096726857E-12 |
| Tall-VS-Follicular |
1.110220E-02 |
| Tall-VS-Other |
8.986800E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
2.689000E-01 |
| Follicular-VS-Normal |
1.78912440418344E-12 |
| Other-VS-Normal |
9.2670999762845E-09 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.63324909152607E-12 |
| Normal-vs-N1 |
1.62536650805123E-12 |
| N0-vs-N1 |
2.005800E-01 |
|
|
